# LifeShare Blood Center – FDA Inspection, Mar 10, 2023

Source: https://www.keypedia.com/records/fda_inspections/lifeshare-blood-center/c663f555-f0f3-4c3d-9a7d-2c96637aeb8c
Source feed: FDA_Inspections

> FDA inspection 1201009 of LifeShare Blood Center, March 10, 2023. Classification: No Action Indicated (NAI). 5 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1201009
- Company Name: LifeShare Blood Center
- Inspection Date: 2023-03-10
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Vaccines and Allergenic Products
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1112129 - 2019-11-19
- FDA Inspection 1022399 - 2017-07-26
- FDA Inspection 887057 - 2014-07-10
- FDA Inspection 759971 - 2011-12-21
- FDA Inspection 628310 - 2009-11-03

## Related Officers

- [Company Rep](https://www.keypedia.com/people/randy-l-clarida/aae3cc15-a908-4489-9299-7542370ad3cd)

Company: https://www.keypedia.com/companies/lifeshare-blood-center/e1707c60-8e43-4429-b543-0a9e2e85cdc6

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
